US is requiring weight-loss drug makers to warn about possible loss of eyesight

Our verdict

This is a centered, straightforward health regulatory report that presents the FDA warning and lets both Novo Nordisk and Eli Lilly respond. Its strength is sourced numbers with comparators and caveats, including the companies' dispute and other risk factors. Readers should keep in mind the very low absolute risk and that causality is still described as potential, not proven.

Why this lean

No left/right framing, sourcing or word choices. Story is regulatory health news told through FDA data and responses from both drugmakers, without partisan actors, labels, or policy arguments.

Framing

The story is told from a public-health regulator angle, with the central question being what risk the FDA found and what the new warning requires.

Key Findings

1. 1Balances regulatory claim with industry rebuttal in direct quotes: FDA says 'there is a potential increased risk' while Novo says data 'do not establish a cause-and-effect relationship'.
2. 2Provides absolute and comparative risk rather than relative risk alone: 'about six cases of NAION per 100,000 people taking GLP-1 drugs every year' compared with 'about four cases among those taking a placebo'.
3. 3Includes context that cuts against alarm: lists other NAION risk factors such as smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease, and notes underlying cause is not completely understood.
4. 4Headline and lede do not overclaim: headline says 'possible loss of eyesight' and body specifies rare NAION that 'can cause permanent vision loss'.
5. 5Usage and tolerability context is sourced: 28 million users via Gallup and discontinuation finding via named 2025 study size, avoiding unsourced generalizations.

Who gets a voice

• U.S. Food and Drug Administration

  Federal drug regulator
  Warning justified by potential increased riskMain voice
• Novo Nordisk via Liz Skrbkova

  Maker of Ozempic and Wegovy, U.S. Media and Stakeholder Relations lead
  Data do not establish cause-effect; benefit-risk remains favorableMain voice
• Eli Lilly spokesperson

  Maker of Zepbound and other GLP-1 drugs
  Evaluating FDA update, reviewing dataMinor voice
• American Academy of Ophthalmology

  Medical professional body, May review authors
  Semaglutide-based GLP-1s may double relative NAION riskMinor voice

Dimension Breakdown

Missing Perspectives

• Patients who experienced NAION or vision loss on GLP-1s, whose symptoms and outcomes would show real-world impact.
• Independent ophthalmologist or epidemiologist outside FDA and manufacturers to interpret the 6-vs-4 per 100,000 difference and study limits.

Key Facts

• FDA is requiring GLP-1 makers including Ozempic and Zepbound to warn about rare NAION, according to FDA
• NAION can cause painless decreased vision in one eye from reduced blood flow, sometimes called an 'eye stroke', according to FDA and article description
• FDA analysis of reports and studies of more than 134,000 patients found about 6 NAION cases per 100,000 GLP-1 users per year vs about 4 with placebo or other diabetes medication, according to FDA
• Patients with history of NAION are at increased risk of recurrence, according to FDA
• Novo Nordisk says data do not establish cause-and-effect and it remains confident in benefit-risk profile, according to Liz Skrbkova
• Roughly 28 million Americans take GLP-1 drugs, according to July Gallup poll cited in article
• Roughly half of GLP-1 patients stop within first year partly due to gastrointestinal effects, according to 2025 study of 125,000 patients cited in article